1. Rothenberg, M. L. CPT-11: An original spectrum of clinical activity. Semin. Oncol. 1996, 23, 21–26.
2. Mathijssen, R. H. J.; van Alphen, R. J.; Verweij, J.; Loos, W. J.; Nooter, K.; Stoter, G.; Sparreboom, A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 2001, 7, 2182–2194.
3. Kawato, Y.; Aonuma, M.; Hirota, Y.; Kuga, H.; Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991, 51, 4187–4191.
4. Innocenti, F.; Kroetz, D. L.; Schuetz, E.; Dolan, M. E.; Ramírez, J.; Relling, M.; Chen, P. X.; Das, S.; Rosner, G. L.; Ratain, M. J. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 2009, 27, 2604–2614.
5. Hoskins, J. M.; Goldberg, R. M.; Qu, P. P.; Ibrahim, J. G.; McLeod, H. L. UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters. J. Natl. Cancer Inst. 2007, 99, 1290–1295.